Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919175 · ClinicalTrials.gov registry record · Phase 2
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT03919175: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03919175 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03919175, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.
Interventions
- DRUG Rituximab
- DRUG Umbralisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2024-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03919175
The ClinicalTrials.gov registry entry for NCT03919175 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT03919175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03919175 about?
NCT03919175 is a clinical study titled "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma". This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.
What is the current status of trial NCT03919175?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-09-01. Estimated completion is 2024-05-05.
What interventions are being tested in trial NCT03919175?
The interventions under investigation include: Rituximab (DRUG), Umbralisib (DRUG).
Who is sponsoring clinical trial NCT03919175?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.